RKDA Arcadia Biosciences, Inc.
Price Chart
Executive Summary
Arcadia Biosciences reported Q1 2026 revenue of $1.1M, down 8% YoY from $1.2M, and a net loss of $4.4M ($2.11/share) vs net income of $2.6M ($1.90/share) in Q1 2025. The revenue decline was driven by a $193K revenue reserve release in the prior year, while the net loss was primarily due to a $2.9M loss on the January 2026 warrant inducement offer and $1.5M in other losses. Zola coconut water volumes grew 18% YoY and SG&A hit a record low, but the headline financials deteriorated sharply.
Actionable Insight
The company's cash burn and reliance on dilutive financing (warrant inducement) are the key risks. With only $954K cash and a stated need for additional funding, monitor for a potential equity offering or strategic transaction. The 18% Zola volume growth is a positive signal but insufficient to offset the deteriorating financial profile.
Key Facts
- Q1 2026 total revenue $1.1M, down 8% YoY from $1.2M
- Net loss attributable to common stockholders $4.4M ($2.11/share) vs net income $2.6M ($1.90/share) in Q1 2025
- Loss on January 2026 warrant inducement offer: $2.9M
- Other loss, net: $1.5M
- SG&A decreased 32% YoY to $1.18M, lowest in company history
- Zola coconut water unit volumes increased 18% YoY
- Cash and cash equivalents $954K at March 31, 2026, up from $259K at Dec 31, 2025
- Company states it will require additional funding in the near future
- Gross proceeds of ~$2.1M from exercise of preferred investment options
Financial Impact
Revenue declined $100K (8% YoY); net income swung from +$2.6M to -$4.4M, a $7.0M deterioration driven by $2.9M warrant inducement loss and $1.5M other losses
Risk Factors
- Requires additional funding in the near future; risk of dilutive equity issuance
- Net loss of $4.4M on only $1.1M revenue indicates unsustainable cash burn
- Revenue decline of 8% YoY despite volume growth, due to prior-year reserve release
- Micro-cap with $2M market cap; extreme volatility and liquidity risk
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-223985 |
| Document: 0001193125-26-223985-index.html | 0001193125-26-223985 |
| Document: 0001193125-26-223985.txt | 0001193125-26-223985 |
| 8-K Data (Synthetic) | 0001193125-26-223985 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 14, 2026
26d ago
|
8-K
| $0.9560 $0.9190 | ▲ +3.87% | ▲ +4.83% | $0.9200 (+3.77%) |
|
Apr 30, 2026
5w ago
|
10-K/A
| $1.12 $1.07 | ▼ −4.46% | ▼ −6.81% | $0.9200 (−17.86%) |
|
Apr 3, 2026
9w ago
|
8-K
| $1.30 $1.33 | ▼ −1.92% | ▲ +2.21% | $0.9200 (+29.23%) |
|
Mar 26, 2026
10w ago
|
Press Release
| $1.47 $1.30 | ▼ −11.56% | ▼ −15.43% | $0.9200 (−37.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access